Multiple myeloma therapies are evolving rapidly. Recently, in Portugal, the inhibition of the NFIL3-MYC axis has shown to overcome treatment resistance in high-risk patients. New approaches, such as CAR-T therapies and antibody combinations, are being explored in various countries, including Canada and the USA, with the aim of improving access to treatments.
Made by MielomaAI On November 17, 2026, at 11:05, based on recent news. May contain errors. View news →
In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Monday, 16/11
MRD Ready to Guide Multiple Myeloma Treatment Decisions?MedPage Today · 17:32 Tratamentos'MRD is becoming a very valuable tool, but it's not an exclusive tool,' says expert
Next-Generation Multiple Myeloma Therapies Market to ReachopenPR.com · 16:44 TratamentosNovember 16 2026 Multiple myeloma treatment is expanding across antibody combinations CAR T cell therapies and newer immune modifying drugs Recent U S approvals have brought some options into earlier treatment lines while new subcutaneous formulations are changing how antibody ...
Tempest acquires rights to experimental myeloma treatmentRare Cancer News · 16:28 TratamentosTempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental treatment for myeloma.
Sanofi and the Alliance Pharmaceutical PanCanadian sign a letter of intent for Sarclisa® (isatuximab), a further step towards public access for newly diagnosed patients with multiple myeloma who are not eligible for a transplant.PR Newswire Canada (Canada) · 14:15 TreatmentsCan you provide the French text you want me to translate?FR/CNW/ -- Sanofi announced today the happy conclusion of negotiations with the Canadian Alliance Pharmaceutical (CPP), marked by the signing of a...
Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System AnalysisOncodaily · 11:23 TratamentosTeclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis / BCMA, BCMA × CD3 bispecific antibody, Daratumumab, FDA
Friday, November 13
Six jobs for AI in myeloma care, from Prerna Mewawalla, M.D.Managed Healthcare Executive · 19:24 TratamentosOnly 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.
Warburg Trap Therapy Selectively Triggers Apoptosis in Multiple Myeloma Cells in VitroBioengineer.org · 14:25 TratamentosA laboratory study demonstrates that combining mitochondrial complex I inhibitors with proton ionophores selectively triggers apoptosis and disrupts energy balance in multiple myeloma cells in vitro.
Wednesday, 11/11
- Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D CandidateGlobeNewswire (Internacional) · 13:53 TratamentosInternacional
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D...
Legend Biotech shares tumble as Carvykti outlook overshadows profitBamboo Works · 04:23 Tratamentos
Wednesday, 11/04
Modern rises 8% on early multiple myeloma data for its three-in-one mRNA therapy.TIKR.com · 08:00 TreatmentsPTSmall trial, big idea.
Tuesday, November 3rd
Advanced imaging tool improves detection of residual multiple myeloma diseaseNews-Medical (Internacional) · 08:00 TratamentosInternacionalA targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.
Thursday, October 29th
Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaBusiness Wire (Internacional) · 07:00 TratamentosInternacional
